Actor Aruna Irani recently revealed she kept her breast cancer diagnosis private. While she initially avoided chemotherapy ...

Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

Researchers evaluated current treatment patterns and clinical outcomes for patients with HER2-positive metastatic breast cancer.

The pathologists evaluated 20 breast cancer cases across three exams in masterclass sessions. They manually scored slide images of five cases in exam A and seven in exam B, with a lecture on HER2 ...

New data shed light on the best strategies for managing patients who develop interstitial lung disease while being treated ...

Medically reviewed by Katlein Franca, MD Skin cancer is a type of cancer that begins in the skin cells, and its appearance can vary widely depending on the type of cancer. Understanding the variations ...

The following is a summary of "Advances and challenges in targeted therapies for HER2-amplified colorectal cancer," published in the April 2025 issue of the European Journal of Cancer by Pizzamiglio ...

Trastuzumab deruxtecan plus pertuzumab significantly extends PFS compared to THP in HER2-positive metastatic breast cancer. The combination demonstrated a 44% lower risk of disease progression or ...

Patients with Stage II and III (early-stage) HER2+ breast cancer usually undergo preoperative therapy with multi-agent chemotherapy in combination with anti-HER2 antibodies, followed by surgery.

The combination of trastuzumab deruxtecan (Enhertu) with pertuzumab (Perjeta) as a first-line treatment for HER2-positive advanced metastatic breast cancer has been shown to reduce the risk for ...